Both these sets of results are consistent with a growing body of evidence that supports cortical cholinergic loss accompanying the transition to dementia in Parkinson’s disease.3 They also provide an important mechanistic rationale for the use of cholinesterase inhibitors in patients with Parkinson’s disease dementia. Here, BCHE is linked to dementia.